# Impact of Estradiol Addback

> **NCT01862835** · PHASE1 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 43 (actual)

## Conditions studied

- Normal Healthy Volunteers

## Interventions

- **DRUG:** Degarelix
- **DRUG:** Testosterone
- **DRUG:** Anastrozole
- **DRUG:** Estrogen patch

## Key facts

- **NCT ID:** NCT01862835
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05
- **Primary completion:** 2016-09-30
- **Final completion:** 2018-12-30
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2019-06-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01862835

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01862835, "Impact of Estradiol Addback". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT01862835. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*